RNG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. RNG is in a clear downtrend (bearish moving-average stack and weakening MACD), and there are no proprietary Intellectia buy signals today to justify an impatient entry. While the stock is near support and options positioning is mildly bullish (put/call ratios < 1) with hedge funds accumulating, the prevailing technical momentum remains negative and fundamentals show weak profitability, making the risk/reward unattractive for an immediate buy.
Trend is bearish. The moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), signaling persistent downside pressure. MACD histogram is -0.17 and negatively expanding, indicating bearish momentum is increasing rather than stabilizing. RSI_6 at ~28.6 suggests the stock is getting short-term oversold, which can produce a bounce, but oversold alone is not a durable buy signal when MACD is still deteriorating. Price (25.55) is sitting just above S1 (25.373) with the next downside support at S2 (24.693). Upside resistance is near the pivot (26.473) then R1 (27.573). With the market also down (S&P 500 -0.69%), near-term follow-through could stay weak unless RNG reclaims 26.47 decisively. Pattern-based projection provided shows a small expected next-day move (+0.16%) but a stronger next-week rebound probability (+14.23%), consistent with a potential oversold bounce attempt rather than a confirmed trend reversal.
Intellectia Proprietary Trading Signals
with unusually high activity, which can fuel a short-term bounce. Next earnings is scheduled for 2026-02-19 (after hours), which can act as a sentiment/catalyst window if guidance improves.
Technical trend is firmly bearish (bearish MA stack; MACD momentum worsening), increasing the odds that support near ~25.37 breaks. No supportive news flow in the last week (no fresh catalysts to reverse momentum). Analyst commentary highlights enterprise pressure expected to persist through 2026, implying reacceleration is not imminent. The broader market tape is risk-off today (S&P 500 down), which can weigh on smaller-cap tech names.
Latest quarter: 2025/Q3. Revenue grew to $638.655M (+4.91% YoY), and gross margin improved to 71.76% (+1.93% YoY), indicating the core model remains resilient on top-line and margin. However, profitability deteriorated sharply: net income fell to $17.559M (-323.60% YoY) and EPS to $0.19 (-311.11% YoY), signaling earnings power is currently unstable (whether from operating pressure, mix, or one-time items). Net: growth is steady but earnings quality is the key drag.
Recent visible update (2025-11-04): Morgan Stanley kept an Equal Weight rating and raised the price target to $31 from $29. The tone is balanced—Q3 was in-line, momentum exists in platform extensions/SMB/GSP, but enterprise remains pressured with reacceleration pushed out (headwinds potentially through 2026). Wall Street pros: improved PT and acknowledgment of pockets of momentum plus margin improvement. Cons: continued enterprise weakness and delayed reacceleration, which aligns with today’s bearish price action. No recent insider trend (neutral) and no recent congress trading data; no notable politician/influential-figure trades provided.
